Published ResearchUnderestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetesNovember 21, 2024
Health SystemsHelix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse PopulationsNovember 13, 2024
Published ResearchA novel method for predicting Lp(a) levels from routine outpatient genomic testing identifies those at risk of cardiovascular disease across a diverse cohortNovember 4, 2024
Published ResearchInfluence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studyNovember 3, 2024
Health SystemsHelix to Showcase the Impact of Clinico-Genomic Research on Clinical Care and Drug Discovery at ASHG Annual MeetingOctober 30, 2024
Published ResearchReduced Likelihood of Hospitalization With the JN.1 or HV.1 Severe Acute Respiratory Syndrome Coronavirus 2 Variants Compared With the EG.5 VariantAugust 6, 2024
Life SciencesHelix appoints Genentech and Flatiron Health Vet Hylton Kalvaria as SVP of Life SciencesMarch 19, 2024
Public HealthPreventable hospitalizations with increased oral SARS-CoV-2 antiviral treatmentFebruary 5, 2024
Published ResearchThe Potential of Genetics in Identifying Women at Lower Risk of Breast CancerDecember 29, 2023
Population GenomicsOptimizing Mammogram Screenings: A Genetic Approach to a Personalized Screening ScheduleDecember 29, 2023
Public HealthInsights from IDWeek 2023: Viral SARS-CoV-2 rebound in untreated and anti-viral treated patientsDecember 4, 2023
